A prospective double-blind randomised placebo-controlled repeated cross-over trial evaluating the efficacy, acceptability, safety and tolerability of Wafermine administered as a first-line treatment for patients with advanced cancer suffering from moderate to severe pain
Latest Information Update: 22 Jun 2021
Price :
$35 *
At a glance
- Drugs Ketamine (Primary)
- Indications Pain
- Focus Therapeutic Use
- 22 Jun 2021 New trial record
- 15 Jun 2021 According to an IX BIOPHARMA media release, the results of this study will assist in the conduct of a definitive trial in guiding physicians on the use of Wafermine to treat cancer pain
- 15 Jun 2021 According to an IX BIOPHARMA media release, this study will be led by Dr Yi-Ching Lee, Consultant Pain Specialist in Chris OBrien Lifehouse & Royal Prince Alfred Hospital.